Anti-CD19 CAR-T cell therapy (Uppsala University)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAnti-CD19 CAR-T cell therapy (Uppsala University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUppsala University

China Registration ClassN/A

Develop Information

Active CompaniesUppsala University Hospital Uppsala University

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A